Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations-Reference-Cited by-同舟云学术

Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations

Published:2018-03 Issue:2 Volume:56 Page:179-183
ISSN:2212-5345
Container-title:Respiratory Investigation
language:en
Short-container-title:Respiratory Investigation

Author:

Goto Ayano,Ozawa Yuichi,Koda Keigo,Akahori Daisuke,Koyauchi Takashi,Amano Yusuke,Kakutani Takuya,Sato Yoshiko,Hasegawa Hirotsugu,Matsui Takashi,Yokomura Koshi,Suda Takafumi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference26 articles.

1. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial;Park;Lancet Oncol,2016

2. Randomized Phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L;Urata;J Clin Oncol,2016

3. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activatingEGFRmutations: Subgroup analysis of LUX-Lung 3;Kato;Cancer Sci,2015

4. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial;Wu;Lancet Oncol,2014

5. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J Clin Oncol,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determination of Afatinib in Human Plasma by 2-Dimensional Liquid Chromatography;Pharmacology;2022

2. Review of chemotherapy‐associated paronychia;International Journal of Dermatology;2021-07-09

3. Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer;BMC Cancer;2020-04-06

4. Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study);Translational Lung Cancer Research;2019-08

5. Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment;Clinical Journal of Oncology Nursing;2018-10-01